0 CHECKOUT
Global Personalized Medicine Partnering 2010-2015: Deal trends, players, financials and forecasts Product Image

Global Personalized Medicine Partnering 2010-2015: Deal trends, players, financials and forecasts

  • ID: 2300222
  • June 2015
  • Region: Global
  • 1546 Pages
  • CurrentPartnering

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1000 links to online copies of actual personalized medicine deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important READ MORE >

Note: Product cover images may vary from those shown

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in personalized medicine dealmaking

2.1. Introduction
2.2. Personalized medicine partnering over the years
2.2.1 Biomarker partnering over the years
2.2.2 Companion diagnostic partnering over the years
2.2.3 Pharmacogenomics partnering over the years
2.3. Big pharma personalized medicine dealmaking activity
2.3.1 Big pharma biomarker, companion diagnostic and pharmacogenomics dealmaking activity
2.4. Most active in personalized medicine
2.5. Personalized medicine partnering by deal type
2.5.1 Biomarker partnering by deal type
2.5.2 Companion diagnostic partnering by deal type
2.5.3 Pharmacogenomics partnering by deal type
2.6. Personalized medicine partnering by disease type
2.6.1 Biomarker partnering by disease type
2.6.2 Companion diagnostic partnering by disease type
2.6.3 Pharmacogenomics partnering by disease type

Chapter 3 - Average financial deal terms for personalized medicine partnering

3.1 Personalized medicine headline values by year
3.2 Personalized medicine upfront payments by year
3.3 Personalized medicine milestone payments by year
3.4 Personalized medicine royalty rates by year

Chapter 4 - Leading biomarker deals

4.1. Introduction
4.2. Top biomarker deals by value

Chapter 5 - Leading companion diagnostic deals

5.1. Introduction
5.2. Top companion diagnostic deals by value

Chapter 6 - Leading pharmacogenomics deals

6.1. Introduction
6.2. Top pharmacogenomics deals by value

Chapter 7 - Big pharma personalized medicine deals

7.1. Introduction
7.2. How to use big pharma personalized medicine partnering deals
7.3. Big pharma personalized medicine partnering company profiles

Chapter 8 - Biomarker contracts dealmaking directory

8.1. Introduction
8.2. Biomarker partnering deals with a contract available by company A-Z
8.3. Biomarker partnering deals with a contract available by by deal type
8.4. Biomarker partnering deals with a contract available by therapy type

Chapter 9 - Companion diagnostic contracts dealmaking directory

9.1. Introduction
9.2. Companion diagnostic partnering deals with a contract available by company A-Z
9.3. Companion diagnostic partnering deals with a contract available by deal type
9.4. Companion diagnostic partnering deals with a contract available by therapy area

Chapter 10 - Pharmacogenomics contracts dealmaking directory

10.1. Introduction
10.2. Pharmacogenomics partnering deals with a contract available by company A-Z
10.3. Pharmacogenomics partnering deals with a contract available by deal type
10.4. Pharmacogenomics partnering deals with a contract available by therapy area

Chapter 11 - Personalized medicine dealmaking directory by specific technology type
Biomarkers
Companion Diagnostics
Pharmacogenomics
Personalized medicine

Chapter 12 - Future trends and companies in personalized medicine deal making
12.1. Introduction
12.2. Emerging companies to watch in 2015
12.3. Emerging companies dealmaking in 2010-2015
12.4. Emerging company financings in 2010-2015

Conclusion

Personalized medicine partnering resource center

Online personalized medicine partnering
Personalized medicine partnering events
Further reading on personalized medicine dealmaking
About
Current Partnering
Current Agreements
Recent titles from Current Partnering
Order Form - Upgrades to subscription access products
Order Form - Reports

Appendix

Appendix 1: Personalized medicine deals by company A-Z
Appendix 2: Personalized medicine deals by deal type
Appendix 3: Personalized medicine deals by therapy type

Table of figures

Figure 1: Personalized medicine partnering since 2010
Figure 2: Biomarker partnering since 2010
Figure 3: Companion diagnostics partnering since 2010
Figure 4: Pharmacogenomics partnering since 2010
Figure 5: Big pharma - top 50 - personalized medicine deals 2010 to 2015
Figure 6: Big pharma personalized medicine deal frequency - 2010 to 2015
Figure 7: Big pharma - top 50 - biomarker, companion diagnostic and pharmacogenomics deals 2010 to 2015
Figure 8: Big pharma biomarker deal frequency - 2010 to 2015
Figure 9: Big pharma companion diagnostic deal frequency - 2010 to 2015
Figure 10: Big pharma pharmacogenomics deal frequency - 2010 to 2015
Figure 11: Most active in personalized medicine partnering 2010-2015
Figure 12: Most active in biomarkers partnering 2010-2015
Figure 13: Most active in companion diagnostic partnering 2010-2015
Figure 14: Most active in pharmacogenomics partnering activity 2010-2015
Figure 15: Personalized medicine partnering by deal type since 2010
Figure 16: Biomarker partnering by deal type since 2010
Figure 17: Companion diagnostics partnering by deal type since 2010
Figure 18: Pharmacogenomics partnering by deal type since 2010
Figure 19: Personalized medicine partnering by disease type since 2010
Figure 20: Personalized medicine partnering by oncology target since 2010
Figure 21: Biomarker partnering by disease type since 2010
Figure 22: Biomarker partnering by oncology target since 2010
Figure 23: Companion diagnostics partnering by disease type since 2010
Figure 24: Companion diagnostic partnering by oncology target since 2010
Figure 25: Pharmacogenomics partnering by disease type since 2010
Figure 26: Pharmacogenomics partnering by oncology target since 2010
Figure 27: Personalized medicine deals with a headline value by year- 2015
Figure 28: Personalized medicine deals with a headline value by year- 2014
Figure 29: Personalized medicine deals with a headline value by year- 2013
Figure 30: Personalized medicine deals with a headline value by year- 2012
Figure 31: Personalized medicine deals with a headline value by year- 2011
Figure 32: Personalized medicine deals with a headline value by year- 2010
Figure 33: Personalized medicine deals with an upfront value by year- 2015
Figure 34: Personalized medicine deals with an upfront value by year- 2014
Figure 35: Personalized medicine deals with an upfront value by year- 2013
Figure 36: Personalized medicine deals with an upfront value by year- 2012
Figure 37: Personalized medicine deals with an upfront value by year- 2011
Figure 38: Personalized medicine deals with an upfront value by year- 2010
Figure 39: Personalized medicine deals with a milestone value by year- 2015
Figure 40: Personalized medicine deals with a milestone value by year- 2014
Figure 41: Personalized medicine deals with a milestone value by year- 2013
Figure 42: Personalized medicine deals with a milestone value by year- 2012
Figure 43: Personalized medicine deals with a milestone value by year- 2011
Figure 44: Personalized medicine deals with a milestone value by year- 2010
Figure 45: Personalized medicine deals with a royalty rate value by year- 2015
Figure 46: Personalized medicine deals with a royalty rate value by year- 2014
Figure 47: Personalized medicine deals with a royalty rate value by year- 2013
Figure 48: Personalized medicine deals with a royalty rate value by year- 2012
Figure 49: Personalized medicine deals with a royalty rate value by year- 2011
Figure 50: Personalized medicine deals with a royalty rate value by year- 2010
Figure 52: Top biomarker deals by value since 2010
Figure 53: Top companion diagnostic deals by value since 2010
Figure 54: Top pharmacogenomics deals by value since 2010
Figure 55: Online partnering resources
Figure 56: Forthcoming partnering events

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: A printed copy of the report and CD ROM copy will be shipped to you. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Corporation
  • Merck & Co., Inc.